QURE uniQure NV

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

• Cowen 41st Annual Health Care Conference, March 1 - 4, 2021
  • Members of uniQure’s management team including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research & development, will participate in virtual one-on-one investor meetings throughout the day on Monday, March 1.
  • David Cooper, M.D., vice president of clinical research CNS, will participate on a panel discussion entitled “Developing and Commercializing Neurological Therapies” on Thursday, March 4 at 1:30 p.m. ET. Registered conference attendees will have access to the live panel webcast.
• H.C. Wainwright Global Life Science Conference, March 9 - 10, 2021
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, March 9.
  • A pre-recorded fireside chat with Matt Kapusta can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website on Tuesday, March 9 starting at 7:00 a.m. ET.
• 2nd Annual Gene Therapy for Blood Disorders, March 9 - 11, 2021
  • Nick Li, Ph.D., M.B.A., senior director, global/US market access lead, will present at a workshop entitled “Developing a Gene Therapy Payment Model & Pricing Strategy for Hemophilia when Alternative Treatments are Available” on Thursday, March 11.
• Gene Therapy Patient Engagement, March 23 - 25, 2021
  • Daniel Leonard, senior director of global patient advocacy, will participate in a panel discussion entitled “What Does Committing to a Gene Therapy Clinical Trial Mean?” starting at 10:00 a.m. ET on Thursday, March 25.
  • Edgar Vega, senior manager of patient advocacy, will present at a workshop entitled “Developing and Distributing Educational Materials on Gene Therapy in a Digital World” starting at 1:30 p.m. ET on Thursday March 25 and will then participate in a panel discussion entitled “What Role and Responsibility do Gene Therapy Companies Have as a Source of Relevant Information for their Communities” starting at 2:30 p.m. ET.
• Stifel CNS Day, March 31 – April 1, 2021
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, March 31.
  • A fireside chat with Matt Kapusta will take place on Wednesday, March 31 from 11:00 to 11:25 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. CantorDirect: 339-970-7536m.cantor@uniQure.com	Chiara RussoDirect: 617-306-9137c.russo@uniQure.com	Tom MaloneDirect: 339-970-7558t.malone@uniQure.com